Detalhe da pesquisa
1.
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.
Eur Urol
; 85(3): 274-282, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37271630